Menu

HISTORY

 

2017

FORTIFY study initiated for CERAMENT®|G*

CERAMENT® V second generation launched with CERAMENT® | Delivery System and all components sterile

2016

FDA approval to initiate pivotal IDE clinical study of CERAMENT®|G* in USA


Paper in Nature Scientific Reports demonstrates the potential of the CERAMENT® drug-eluting platform. Publication entitled 'A Biphasic Calcium Sulphate Hydroxyapatite Carrier Containing Bone Morphogenic Protein-2 and Zoledronic Acid Generates Bone' (Raina, D et al).


Publication in The Bone and Joint Journal demonstrates the utility of CERAMENT®|G in the management of chronic osteomyelitis. Paper entitled 'Single-stage treatment of chronic osteomyelitis with a new absorbable gentamicin-loaded, calcium sulphate/hydroxyapatite biocomposite - A prospective series of 100 cases' (McNally et al, The Bone and Joint Journal, 2016, Vol. 98-B, No. 9, p1289-96).

 

Richard Davies appointed as CEO

 

FY 2016 sales of SEK 105m (70% YoY growth)

2015

CE-mark approval for CERAMENT® V the first vancomycin antibiotic eluting injectable ceramic bone graft substitute


CERAMENT®|BONE VOID FILLER and CERAMENT®|G* launched with new CERAMENT®|Delivery System

 

PMA device pathway for CERAMENT®|G confirmed by FDA in the US

2013

CE-mark approval for CERAMENT®|G*, the first antibiotic eluting injectable ceramic bone graft substitute

2012

Distribution agreement with Biomet Inc for USA and Canada for CERAMENT®|BONE VOID FILLER

2009

CE-mark approval for CERAMENT®|BONE VOID FILLER

2008

CE-mark approval for CERAMENT®|SPINE SUPPORT 

2005

CERAMENT®|BONE VOID FILLER is cleared to be marketed and sold in the US

1999

BONESUPPORT AB founded by Dr. Lars Lidgren, Professor in Orthopedic Surgery at Lund University and an internationally respected scientist

*Not available in the United States, for investigational use only
Not available in the United States